Biofrontera (BFRI) Convertible Debt (2024 - 2025)
Biofrontera (BFRI) recorded quarterly Convertible Debt of $4.6 million in Q4 2025, up 2.85% quarter-over-quarter from $4.5 million in Q3 2025, and up 11.98% on a YoY basis from $4.1 million in Q4 2024.
Biofrontera (BFRI) Convertible Debt (2024 - 2025) Analysis & Trends
Biofrontera's Convertible Debt history runs 2 years deep, the most recent figure standing at $4.6 million for Q4 2025.
- In Q4 2025, Convertible Debt rose 11.98% year-over-year to $4.6 million; the TTM figure through Dec 2025 stood at $4.6 million (up 11.98% YoY), while the FY2025 annual figure was $4.6 million, up 11.98% from the prior year.
- Convertible Debt was $4.6 million for Q4 2025 at Biofrontera, up from $4.5 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $4.6 million in Q4 2025 to a low of $4.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Biofrontera | 8.65 Mn | 2.24 Mn | 14.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.59 Mn |
| Sep 30, 2025 | 4.46 Mn |
| Jun 30, 2025 | 4.34 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Dec 31, 2024 | 4.10 Mn |